Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Curr Pharm Des. 2012;18(22):3215–3221. doi: 10.2174/1381612811209023215

Figure 3. Relapse-free survival in patients with MDS or AML conditioned with fludarabine plus treosulfan and transplanted from HLA matched related or unrelated donors.

Figure 3

Shown are the results based on cytogenetic risk (per IPSS criteria for MDS, and per cooperative group criteria for AML). Reprinted from Biology of Blood and Marrow Transplantation. Conditioning with Treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. E.R. Nemecek, K.A. Guthrie, M.L. Sorror, B.L. Wood, K.C. Doney, R.A. Hilger, B.L. Scott, T.J. Kovacsovics, R.T. Maziarz, A.E. Woolfrey, A. Bedelov, J.E. Sanders, J.M. Pagel, E.J. Sickle, R. Witherspoon, M.E. Flowers, F.R. Appelbaum, H. Joachim Deeg, Biology of Blood and Marrow Transplantation 2011; 17:341–350. © 2011, with permission from Elsevier.